Purpose: To learn the extent to which HMOs and academic genetic centers (1) are involved in predictive genetic tests for common, complex disorders and (2) interact with each other. Methods: Surveys of HMO medical directors and directors of U.S. academic genetic centers. Results: In 1996, approximately 28% of HMOs were covering predictive tests for breast and colon cancer, but 75% of all medical directors said their HMO would consider policies regarding predictive testing in the next 5 years. Approximately 80% of directors of academic genetic centers said they provided genetic counseling services for common adult-onset disorders for patients covered by managed care organizations (MCOs), but they ranked the volume of services they provide for pediatric and prenatal indications much higher. Most academic genetic centers (72%) have contracts with MCOs. Conclusion: Although genetic services are being provided by academic genetic centers to patients who are members of managed care organizations, many patients with whom genetic testing for adult onset disorders is discussed may never see a geneticist. Academic genetic centers should educate nongeneticist professionals about the use of tests for common disorders. Genetics in Medicine, 1999:1(6):272-285.
Within the past 10 years, tests for predicting genetic susceptibility to Alzheimer disease, breast cancer, colon cancer, and other common adult-onset disorders have been developed. The extent of demand for these tests should depend on the strength of the associations between genotypes and diseases (clinical validity) and evidence on the safety and effectiveness of interventions to reduce risk and/or improve outcomes (utility) in those found by testing to be at increased risk.' At present, clinical laboratories can market tests for which clinical validity and utility have not been established. ' Lack of data on validity and utility affects the willingness of health insurers, including managed care organizations, to cover predictive genetic tests.' In 1995, fewer than 16% of 166 health insurers had ever made a decision to cover breastlovarian cancer (BRCA) susceptibility testing2 The high cost of these tests limits their diffusion into practice as many people cannot afford to pay for them out-of-pocket. Fear that insurers will discriminate against those with positive test results has also limited interest in although state and federal legislation has been slowly reducing the potential for discrimination. 5 Despite the limited diffusion, the rapid pace of genetic discoveries and increased media coverage suggest that predictive genetic testing could play an expanding role in medical care. We wanted to learn more about the state of such testing, as well as the involvement of geneticists, among health maintenance organizations (HMOs) and managed care organizations (MCOs). In the first of the two surveys reported here, we attempted to learn the extent to which HMOs received requests for and were covering predictive genetic tests for breast cancer, colon cancer, and Alzheimer disease (AD), and whether they had established arrangements with genetic specialists. We selected HMOs because nearly 80 million people (over one-quarter of the population) were enrolled in them in the United States and Puerto Rico in 1996, and because their enrollment had increased 57.5% between 1993 and 1996.6 HMOs were also more likely than preferred provider organizations, indemnity plans, or self-insured plans to cover established genetic technologies and other genetic services (Schoonmaker et al., unpublished data, 1999) . At the time of the survey, tests for inherited susceptibility were available for mutations at the BRCAl and 2 loci, at several different loci for hereditary nonpolyposis colon cancer, and for the apolipoprotein E-€4 polymorphism, which had been associated with AD. However, the American Society of Human Genetics recommended that predictive testing for breast cancer should be conducted on an investigational basis6 and several organizations opposed use of the ApoE-~4 test to predict risk of Alzheimer disease as there was no treatment or prevention for the d i s e a~e .~
We were also interested in learning the extent to which geneticists were providing services for adult-onset conditions. The existence of tests that detect inherited predispositions does not necessarily mean that geneticists will be the ones who offer or interpret them. The three common disorders for which tests are available are often managed by nongeneticist specialists in conjunction with primary care providers. These nongeneticists could offer predictive tests, as well as interpret the results. In order to learn more about geneticists' role we also surveyed directors of academic genetic units in the United States. Compared with private genetic units, academic genetic units are more readily identifiable and are also likely to be the genetic centers receiving the largest number of referrals.
We also used the two surveys to learn more about the relations between managed care organizations and clinical geneticists, and to learn in which laboratories genetic tests are being performed.
Survey of HMOs

Written survey
A one-page questionnaire was mailed in September, 1996 to 535 medical directors listed in the directory of the American Association of Health Plans (AAHP).9 Medical directors of HMOs who failed to respond were remailed the questionnaire. In the cover letter accompanying the survey, medical directors were asked to forward the questionnaire to someone else in their organization if that person was better able to complete it.
A preliminary draft of the questionnaire was pilot-tested in two stages. In the first, the HMO Group, a national association of nonprofit HMOs covering over six million HMO subscribers, agreed to fax a draft to its 29 member organizations. Based on the responses from 22 medical directors, the questionnaire was modified. The modified draft was sent to experts in the field of managed care. Their few suggestions were incorporated. Although wording differed, the pilot and final questionnaire were quite similar in content. Hence, the 22 HMO Group respondents were included in the analysis.
The final one-page questionnaire consisted of three sections of close-ended questions (See Appendix for the final questionnaire). The first section elicited information regarding four adult-onset disorders: breastlovarian cancer, colon cancer, Alzheimer disease, and Huntington disease. For each disorder, we asked respondents to indicate (a) if they had ever received requests from providers for predictive genetic testing; (b) if they had ever covered the request; and c) if they had a written policy regarding coverage for predictive genetic testing. Although it is much less common, we included Huntington disease because it is an adult-onset disorder for which testing criteria are well-established. The second section asked respon-) dents if they expected their HMO to consider developing policies regarding predictive genetic testing for adult disorders in the next 1-5 years. The third section asked respondents about the types of arrangements the HMO had established with genetic specialists (employ, contract with, or consult informally). Genetic specialists were defined as medical geneticists, genetic counselors, and nurses trained in genetics.
Telephone follow-up
Respondents to the one-page questionnaire who indicated that they either had covered predictive genetic testing for breastlovarian cancer, colon cancer, or Alzheimer's disease ( n = 42) or had coverage policies for predictive genetic testing ( n = 8 HMO Group members) were contacted by telephone. As part of the phone interview, we asked respondents to confirm andlor clarify their responses to the written survey regarding requests for and coverage of predictive tests. We also asked about factors that were or would be important in establishing relationships with genetic specialists, as well as whether the HMO had developed any educational programs about genetics for nongenetic health care professionals or patients.
Classification of HMOs
Because of similarities between Network and Individual Practice Association (IPA) HMOs we merged these two categories for purposes of analysis. For the same reason, we also merged Group with Staff HMOs. Respondents that had enrollees in both of these two merged categories are referred to as "Mixed HMOs."
Survey of Directors of Academic Genetic Center Directors
Of the 105 programs listed in The Guide to North American Graduate and Postgraduate Training Programs in Human Genetics,1° 69 in the U.S. listed "clinical genetics" as one of their areas of concentration. They were mailed questionnaires. A draft of the questionnaire was sent to the head of an academic genetics unit for "pilot" testing. His comments were incorporated into the final questionnaire. Some questions used wording parallel to those in the previously pilot-tested HMO questionnaire, and we did not want to change them.
The academic genetic center directors were asked closeended or multiple choice questions, including whether they had contractual arrangements with MCOs, the types of prenatal, pediatric, and adult genetic services they provided to MCOs, the frequency of referrals from MCOs for these services, and issues of coverage they encountered in providing genetic services to patients in MCOs. We used "MCOs" rather than "HMOs" as the more encompassing term that did not require respondents to distinguish between types. The genetic center directors were also asked to indicate the source of patient referrals to them and if their unit had developed any educational materials or programs for nongenetic health care professionals or patients. (See Appendix for the final questionnaire). 
RESULTS
SURVEY OF HMOS
Including the HMO Group, responses were received from 21 1 of the 563 HMOs to whom the questionnaire was mailed (37%). The overall response rate for the phone interview was 78% (39150). Based on the way they were classified in the AAHP database, 132 NetworklIPA HMOs (35%), 19 Group1 Staff HMOs (36O/o), and 34 Mixed HMOs (50%) responded. According to data in the AAHP database, respondent and nonrespondent HMOs did not differ by the number of primary, specialty or total physicians with whom they contract, or whether they met federal qualifications, National Committee on Quality Assurance accreditation, or had a point of service plan.
Coverage of requests
Medical directors of 43% of HMOs reported receiving requests for predictive genetic testing for breast cancer compared with 26%, 23%, and 8% respectively for Huntington disease colon cancer and Alzheimer disease (Table 1) . However, they were more likely to cover testing for Huntington Disease than breast cancer (Chi squared, P = 0.025), colon cancer ( P = 0.019) or Alzheimer disease ( P < 0.001). Only one HMO covered the test for Alzheimer disease. NetworkIIPA HMOs reported covering requests for predictive genetic tests for all three diseases more often than GrouplStaff and Mixed HMOs ( Fig. 1) but only for breastlovarian cancer was the difference significant ( P < 0.001 ).
Differences in mailed versus phone
We were surprised by the relatively large percentage of HMOs reporting that they had actually covered predictive genetic testing for BRCA and colon cancer in view of a 1995 survey showing very sparse coverage for BRCA testing2 Therefore, in the phone interview, we defined predictive genetic testing as testing conducted in healthy individuals to predict risk of future disease. After being given this definition, 12 of the 35 respondents changed their answers. In three of these cases, the person who completed the phone interview was different from the person who completed the written questionnaire. The change in response was uniformly in the direction of fewer 'Among those that received requests n = 211.
requests and fewer decisions to cover. Table 2 summarizes this information and shows that the number of reported requests covered for predictive genetic testing for breast cancer fell from 29 in the written questionnaire to 21 in the phone survey, and those for colon cancer fell from 17 to 1 1.
Percent considering future polices by HMO type
In the written survey, 44% of HMOs reported that they would consider policies for predictive genetic testing in the next one year, and an additional 3 1 % reported that they would consider policies in the next 2-5 years.
Arrangements with genetic specialists by model type
Most HMOs had established relationships with genetic specialists. The most frequently reported arrangement for all types of HMOs was to contract with genetic specialists (65%). We did not determine if these contracts reimburse specialists on a fee-for-service, salary, or capitation basis. Fewer HMOs reported informal arrangements with genetic specialists (35%) and only 6% reported employing genetic specialists. When examined by HMO type, GroupIStaff reported more informal arrangements and more employment of genetic specialists than NetworkIIPA and Mixed HMOs (Fig. 2) .
During the follow-up phone interview, respondents were asked to elaborate on the types of informal arrangements they had with genetic specialists. Most often respondents indicated that they either referred to genetic specialists or bought their services as needed. In a few cases, geography limited establishing formal arrangements with genetic specialists, as there were no genetic specialists available near the HMO.
Factors influencing HMOs to establish arrangements with specialists
During the phone interview, respondents who reported having any type of arrangement with genetic specialists were presented with several factors and asked how important these factors were in influencing them to hire ( n = 3), contract with ( n = 27), and/or establish informal arrangements with (n = 1 1 ) genetic specialists (Fig. 3) . Of the thirty five HMOs reporting at least one of these arrangements, the majority reported the need to offer up-to-date and competitive services, the need to provide cost-effective services, and physician demand as being important factors. Fewer HMOs reported media or public attention, and fear of liability as being important in establishing arrangements with specialists. Six respondents wrote in that genetic specialists were included as part of a larger contract.
Respondents who reported having no arrangement (n = 4) or having informal arrangements with genetic specialists (n = 1 1 ) were asked which of the above factors would be important in influencing them to hire or contract with genetic specialists.
Genetic sewices for complex disorders
Ered>t ~m e r In their responses, the relative importance of these different factors was the same as for those who had arrangements.
Primary responsibilities of genetic specialists
As part of the phone interview, medical directors were also asked about the primary responsibilities of genetic specialists with whom they contract or employ. The majority (52%, n = 15) reported the primary responsibilities of the genetic specialists as being prenatal and/or pediatric. Twenty five percent (n = 7) reported that they contracted with genetic specialists for "all" types of genetic services. Very few contracted with genetic specialists only for adult medicine or cancer related services.
Education
In the phone interview, we also asked if HMOs had ever developed educational programs or brochures about genetics for nongenetic providers or patients. Seven out of 36 reported that their HMO developed such programs for providers, but only one HMO developed material about genetics for patients. More often the HMO reported that the development of educational materials or programs would be left up to the various clinicians in the HMO.
SUWEY OF DIRECTORS OF ACADEMIC GENmIC CENTER DIRECTORS Response rate
The response rate was 78% (54169).
Arrangements with managed care organizations
Seventy-two percent (n = 39) reported that their institution or their genetics unit contracts with managed care organizations. All 15 of the remaining centers reported that they see patients referred by MCOs, although they do not contract with MCOs. Table 3 describes the number of genetic centers providing initial clinical evaluation, genetic testing, genetic counseling, and ongoing medical management for pediatric, prenatal and adult-onset disorder problems. Eighty percent ofgenetics units reported providing genetic counseling and 78% provided testing services for adult-onset disorders to patients enrolled in MCOs; whereas only 37% provide ongoing medical management, a significantly smaller proportion than for pediatric (74%) problems (Chi squared, P < 0.001 ).
Types of services provided
Corroboration of the relative importance of pediatric and prenatal compared with adult-onset problems was obtained by asking respondents to rank the frequency with which they received referrals from managed care organizations, with 1 being the specialty area for which they received the greatest volume of referrals, 2 the next greatest volume, etc. No respondent ranked adult-onset disorders as generating the highest volume of referrals. The mean rank ? SEM was 1.60 2 0.11 for prenatal referrals and 1.62 2 0.10 for pediatric referrals. For adult referrals the mean rank was 2.88 2 0.09, significantly lower than for prenatal and pediatric referrals (t test, P < 0.001 ). We also gave respondents the opportunity to rank other areas. Three respondents wrote referrals for ~eptember/o&ber 1999 -Vol. 1 . No. 6 laboratory services (mean rank = 2.7) and five each named a referred from independent practitioners, followed by MCOs, different service (mean rank = 3.1).
and least by patient self-referrals. It is possible that some referIn order to understand the relative importance of referrals rals from "independent" practitioners were from physicians in from MCOs for genetic services, directors of genetics units IPA type HMOs or Point of Service plans. In addition to the were asked the percentage of patients referred through differabove sources of referrals, six directors of genetics units reent sources (Table 4 ). The highest proportion of patients were ported referrals through medical assistance programs, ten Table 4 Mean percentage of patients referred for genetic services through different sources Other (n = 8)
22
'Write-in responses. Percentages total to greater than 100 because more than one response was possible. n = 52.
through state programs, and three through academic institutions or organizations.
Use of laboratories
Directors of genetics units were asked where they send specimens for genetic testing for susceptibility to common complex adult disorders (Table 5 ). Many centers send specimens to Table 5 Laboratories used for genetic tests for common, complex adult disorders by genetic centers *Percentages add to more than 100 because more than one laboratory is used. For instance, 21 respondents sent specimens to the laboratories listed in the first three rows; 12 to the laboratories listed in rows 2 and 3; and 6 to the laboratories listed in rows 1 and 2. n = 53. more than one laboratory. Although 39 centers sent some specimens to commercial laboratories, only 4 centers sent all their tests to a commercial laboratory (data not shown).
Coverage issues
Five coverage issues that are anecdotally stated to occur in geneticists' relations with MCOs were listed on the questionnaire. Table 6 shows that nearly aU genetic units reported that at least one of these issues had arisen in providing services to patients enrolled in MCOs. Other issues that respondents spontaneously wrote in included genetic evaluation only if the patient is already pregnant, denial of authorization for services, referrals only for the least expensive category of consultation, restrictions due to subcontracts, and problems getting adequate or appropriate referrals. The wording of the question did not permit us to estimate how frequently these issues arose.
Educational programs
Thirty one genetics units (57%) reported that they had developed educational training programs or material for nongenetic health care professionals. The most commonly cited programs were for cancer-susceptibility ( n = 18).
Twenty of the units offered CME credits for at least one of their educational programs. Twenty-two units had developed 
DISCUSSION
HMOs are receiving req~lests for, and ,Ire beginning to cover, predictive genetic testing for common adult-onset conditions. If we assume that one-third of the HMO medical directors who responded to the mail sunrey mistakenly reported that their company covered breast or colon cancer testing, still 28% of HMOs were covering predictive tests for these conditions in 1996. The majority of those covering predictive testing did so on a case-by-case basis, yet three-quarters of HMOs said they would consider policies regarding predictive testing in the nest 5 years. Currently, approximately 94% of insurers (including HMOs) in contact with the major commercial laboratory testing for breast cancer susceptibility cover at least part of the cost of testing, usually on a case-by-case basis, suggesting that genetic susceptibility testing is increasingly become part of medical care."
We did not ask the HMO medical directors which type of specialists saw patients who requested testing for breast or colon cancer. Judging from the responses of academic genetic center directors it seems likely that geneticists are consulted. Eighty percent of genetic center directors said they provided counseling about adult-onset disorders (for which we gave as examples colon cancer and coronary artery disease) and 78% said they were offering or arranging tests for these disorders for patients covered by managed care organizations. This does not mean, however, that most HMO subscribers for whom predictive testing for common disorders is indicated are seen by a geneticist. If they were, it could rapidly become the primary activity of geneticists because of the large numbers of patients at risk for common disorders compared with those at risk for a variety of rare disorders. Providing services for adult-onset disorders was not reported to be the primary activity of geneticists by either the HMOs or the genetic center directors. Both of them reported prenatal and pediatric genetic services as the principal activities of medical geneticists. A much higher proportion of people who may have inherited susceptibility to common, adult-onset disorders may be seen by nongeneticists than by geneticists.
A small survey of managed care organizations in New York suggests that medical directors rely on primary care providers to serve as "gate-keepers" for genetic referrals." Consistent with this was a survey of primary care providers in the Pacific Northwest, in which the majority of the nearly 800 internist and obstetrician/gynecologist respondents said they would provide risk counseling to women at increased risk of breast cancer rather than refer to a specialist.'' The small and stable supply of geneticists and genetic counselors places limits on the proportion of patients that can be seen by genetic specialists, leading to greater reliance on primary care and other nongeneticist practitioners to provide information on genetic testing.141'
HMOs do have formal relations with medical geneticists. There was agreement in the percentage of HMO medical directors who said they had contractual arrangements with geneticists (65%) and genetic center directors who reported having contractual arrangements with MCOs (72%). The most frequently cited reason HMOs gave for establishing relationships with genetic specialists was providing up-to-date and competitive services. In contrast to our finding, a smaller survey of HMOs in New England reported that only seven of 18 responding HMOs (39%) employed or contracted with medical geneticists or genetic counselor^.^^ Even if most HMOs have formal arrangements with geneticists, as our data suggest, this does not mean that they encourage referral to geneticists. In our survey, the vast majority of genetic center directors encountered some difficulties in MCO coverage, for instance, HMOs would not reimburse for evaluation of extended family members and would only authorize one visit to a geneticist. We do not know how often these problems arose.
Although nongeneticist physicians provide information to patients about genetic susceptibility to adult-onset disorders, they may not be optimally prepared to do so. In the Pacific Northwest study, 14% of internists and obstetrician gynecologists did not know that a young woman with two relatives on her mother's side who had breast cancer was at increased risk and 57% did not know that she would be at increased risk ifthe same relatives were on her father's side. A majority of those who did not know the risk was increased said they would provide risk counseling.13 In telephone interviews of physicians who ordered a test for familial adenomatous polyposis, the interpretation of the tests result was incorrect almost one-third of the time (31.6%)." In a national survey in which a comprehensive test of knowledge of genetics and genetic tests was mailed to primary care physicians and psychiatrists, 41% of family physicians who did not deliver babies, and 33.1% of internists answered less than two-thirds of the questions correctly. A lower proportion of family physicians who delivered babies (21.4%), obstetrician-gynecologists (23.5%) and pediatricians (13.4%) answered less than two-thirds correctly.18 That the validity and utility of genetic tests for common disorders often has not been, and legally need not be, established before they become clinically available1 exacerbates deficiencies in health care providers' knowledge.
Regardless of whether referrals are generated or not, geneticists should educate other health care practitioners about inherited susceptibility and the indications for, as well as the benefits and risks of, predictive genetic tests. Over half of the genetic directors we surveyed, reported that they were developing educational materials on adult disorders for other health practitioners (57%). The most frequently cited category for both groups was cancer susceptibility. It would be useful to examine the content of these materials and the effectiveness of the efforts of genetic centers to improve knowledge of geneticsand related clinical performance-of primary care and other nongeneticist physicians. An analysis of materials made available by clinical laboratories offering genetic tests indicated inaccuracies in information presented to health care providers and patients.'
Geneticists were limited by HMOs in the laboratories they could use for genetic testing (Table 6 ). With biotechnology companies that provide tests stalung out patent claims and stringent licensing agreements, it is doubtful that laboratories in academic centers will ever attract referrals for adult-onset disorders as they do for rare, single gene disorders. Almost three-quarters of genetic units used commercial laboratories for some genetic tests for adult-onset disorders. A recent paper expressed alarm that large commercial laboratories were replacing academic laboratories as providers of genetic tests."
These surveys had a number of limitations. We limited the first survey to medical directors of HMOs whereas in our survey of directors of academic genetic centers we asked questions about MCOs in general, although HMOs comprise the largest proportion of managed care organizations. The response rate of 37% in the HMO survey was lower than we expected. We did not include a monetary incentive, primarily because our funds were limited, but we did mail the survey a second time to nonrespondents. In a previous study of medical directors of all types of private health insurers, the inclusion of a $1 bill with a one-page survey yielded a 48% response rate, but enclosure of a check for $10 with a longer follow-up survey only yielded a 37% response rate from HMO medical directors.' Variables for which data on nonrespondents were available, did not differ between respondent and nonrespondent HMOs.
We had a better response rate from the directors of the academic genetic units (78%). We cannot, however, generalize to other providers of genetic services, such as private hospitals or free-standing clinics.
A more troublesome concern is the reliability of the written responses to the HMO survey regarding requests for and coverage of predictive genetic tests. In our original script for the telephone follow-up of respondents who said they were covering predictive tests, we did not include a question on requests and coverage for predictive tests. We decided to add this question when we found that a surprisingly large proportion of respondents to the first survey said they were covering predictive tests and that there was a high turn-over rate among medical directors. Efforts to check reliability of mail survey responses are seldom undertaken. Our finding serves as a warning on the reliability of survey responses. We attempted to minimize "wrong" answers in the first, written survey by asking medical directors to forward the questionnaire to someone else in their organization if slhe was better able to answer the questions. It is not clear that this was always done. Eight respondents to the phone survey were not the same person who responded to the written survey. They accounted for only 3 of the 12 responses that changed between the written and phone survey. In considering the implications of our data, we extrapolated from the phone interviews rather than the survey.
CONCLUSIONS
Increasingly, predictive genetic tests for common, complex, adult-onset disorders are being covered by HMOs. Although geneticists are offering these tests, the proportion they provide is unknown and should be the topic of future research. It is doubtful that they provide most of the testing because there are too few genetic specialists available and access to them may be limited by managed care. Nevertheless, geneticists and genetic counselors are more likely to be aware of the tests' limitations than other practitioners whose knowledge of genetics in general and of risks of common disorders in particular is often deficient. In order to ensure appropriate services to people at risk ofcommon disorders either the knowledge ofprimary care and other nongeneticist practitioners about predictive genetic testing must be improved or access to geneticists increased. Academic genetic centers are providing educational materials to other providers. The ability ofthese and other approaches to improve practitioners appropriate use of predictive genetic tests needs evaluation. The AAHP offers the following definitions for the four model types in its National Directory of HMOs:
Staff: An organized prepaid health care system that delivers health services through a salaried physician group that is employed by the HMO Unit. Group: An organized prepaid health system that contracts with one independent group practice to provide health services. Independent Practice Association (IPA): An organized prepaid health care system that contracts directly with physicians in independent practice, with one or more associations of physicians in independent practice, and/or with one or more multi-specialty group practices (but predominantly organized around sololsingle specialty practices) to provide health services. Network: An organized prepaid health system that contracts with two or more independent group practices to provide health services.
4. Please rank tlie frequency with which the genetics unit receives referrals from managed care organizations in each of the areas listed below. The area for which the greatest volume of patients are referred should receive a ranking of 1, the area for which the least volume of patients are referred should receive a ranking of 4. 5. or 6. depending on tlie services tlie unit provides. i. other (specify). 
